RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested whether adding idelalisib to lenalidomide helps people with mantle cell lymphoma that has returned or is resistant to treatment. Lenalidomide boosts the immune system to fight cancer, while idelalisib blocks enzymes that help cancer cells grow. The trial involve…
Matched conditions: RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough lymphoma: experimental drug shows promise
Disease control CompletedThis study tested an experimental drug called ICP-022 in 106 adults with mantle cell lymphoma that had come back or stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check its safety. The approach focuses on controlling the disease…
Matched conditions: RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Engineered immune cells show promise against tough lymphoma
Disease control CompletedThis phase 2 study tested a single infusion of brexucabtagene autoleucel (KTE-X19), a CAR T-cell therapy, in 105 patients with relapsed or refractory mantle cell lymphoma. The treatment aims to help the body's own immune cells recognize and attack cancer. Results showed that many…
Matched conditions: RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Engineered immune cells show promise against tough lymphoma
Disease control CompletedThis phase 2 study tested a personalized cell therapy called KTE-X19 (brexucabtagene autoleucel) in 95 adults with mantle cell lymphoma that had returned or stopped responding to prior treatments. Participants received a single infusion of their own genetically modified immune ce…
Matched conditions: RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC